During a live event, Megan Kruse, MD, discussed NCCN guidelines and key therapies for patients with HR-positive metastatic ...

Omitting endocrine therapy in ER-low breast cancer was associated with a 23% relative increase in the risk of death in 3 ...

Bria-IMT plus check point inhibitors had a median overall survival which outperformed that of antibody-drug conjugates in HR+ ...

BriaCell stock (TSX:BCT) is positioned to the upside after reporting phase 2 survival data for its Bria-IMT cell therapy with ...

Even after the removal of breast tissue, it is possible that the cancer may recur in the chest wall or the area where the ...

Breast cancer subtyping is essential for determining appropriate treatment strategies, as each molecular category, luminal A, ...

Uterine cancer affects 28 in 100,000 women annually. Learn the 5 critical warning signs that could save your life and why ...

The terrifying rise of 'secondary' breast cancer - and the little-known sign that thousands of women could be missingA ...

Researchers have found new compounds that could be used to treat a common breast cancer that can be resistant to hormone ...

If you have metastatic castration-resistant prostate cancer, the hormone therapy you’ve been taking is no longer controlling the disease as it should. Here’s what you should know. This type of ...

“It’s completely unpredictable because hormone cycling ... messaging about the treatment. In 2002, the Women’s Health ...

This is a form of prostate cancer that has spread to other parts of the body and does not respond to standard hormone therapy ...